UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )*
ACORN HOLDING CORP.
------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 Par Value
------------------------------------------------------
(Title of Class of Securities)
004853107
------------------------------------
(CUSIP Number)
April 15, 1998
-------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
CUSIP No. 004853107 SCHEDULE 13G Page 2 of 5
- --------------------------------------------------------------------
(1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons
(entities only)
Allen Landers, M.D.
(2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
(3) SEC Use Only
(4) Citizenship or Place of Organization
United States
Number (5) Sole Voting Power 243,800
of Shares ----------------------------------------------------
Beneficially (6) Shared Voting Power 10,000
Owned by ----------------------------------------------------
Each (7) Sole Dispositive Power 243,800
Reporting ----------------------------------------------------
Person With (8) Shared Dispositive Power 10,000
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
253,800 (See item 4(a) with respect to beneficial ownership.)
(10) Check if the Aggregate Amount in Row (9) Excludes Certain
Shares (See Instructions) [ ]
(11) Percent of Class Represented by Amount in Row 9
6.1%
(12) Type of Reporting Person (See Instructions)
IN
<PAGE>
CUSIP No. 004853107 SCHEDULE 13G Page 3 of 5
- -------------------------------------------------------------------
Item 1(a) Name of Issuer:
Acorn Holding Corp.
Item 1(b) Address of Issuer's Principal Executive Offices:
100 Park Avenue, 23rd Floor, New York, NY 10017
Item 2(a) Name of Person Filing:
Allen Landers, M.D.
Item 2(b) Address of Residence:
The residence address for the Reporting Person is 1385 York
Avenue, #26F, New York, New York 10021.
Item 2(c) Citizenship:
United States
Item 2(d) Title of Class of Securities:
Common Stock, $0.01 Par Value
Item 2(c) CUSIP Number:
004853107
Item 3. If this statement is filed pursuant to rules 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or Dealer registered under section 15 of the Act;
(b) [ ] Bank as defined in section 3(a)(6) of the Act;
(c) [ ] Insurance Company as defined in section 3(a)(19) of the Act;
(d) [ ] Investment Company registered under section 8 of the
Investment Company Act;
(e) [ ] An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act;
(i) [ ] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act.
(j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J)
If this statement is filed pursuant to Rule 13d-1(c), check this box. [X]
<PAGE>
CUSIP No. 004853107 SCHEDULE 13G Page 4 of 5
- -------------------------------------------------------------------
Item 4. Ownership:
(a) Amount Beneficially Owned:
253,800 shares of Common Stock, of which 127,800 of such shares are
held in the Allen Landers M.D., P.C. Profit Sharing Plan and Trust of
which the Reporting Person is a member and the sole trustee.
(b) Percent of Class:
6.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 243,800
(ii) shared power to vote or to direct the vote: 10,000
(iii) sole power to dispose or to direct the disposition of: 243,800
(iv) shared power to dispose or to direct the disposition of: 10,000
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner
of more that five percent of the class of securities, check the
following [ ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
Not applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notices of Dissolution of Group
Not applicable.
<PAGE>
CUSIP No. 004853107 SCHEDULE 13G Page 5 of 5
- -------------------------------------------------------------------
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
Signature
After reasonable inquiry and to the best of his knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: April 24, 1998
Allen Landers, M.D.
-------------------------------
Allen Landers, M.D.
